TWIST is expressed in human gliomas and promotes invasion

Neoplasia

Volumn 7, Issue 9, 2005, Pages 824-837

  Elias, Maria C ^a   Tozer, Kathleen R ^a   Silber, John R ^a   Mikheeva, Svetlana ^a   Deng, Mei ^a   Morrison, Richard S ^a   Manning, Thomas C ^a   Silbergeld, Daniel L ^a   Glackin, Carlotta A ^b   Reh, Thomas A ^c   Rostomily, Robert C ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Brain tumor; Cancer; Invasion; Neuron; Oncogene

Indexed keywords

MESSENGER RNA; PROTEIN P53; TRANSCRIPTION FACTOR TWIST; NUCLEAR PROTEIN; TWIST1 PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; ASTROCYTOMA CELL; CANCER GRADING; CELL INVASION; GENE EXPRESSION; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; ANIMAL; ASTROCYTE; ASTROCYTOMA; BRAIN; CANCER INVASION; CENTRAL NERVOUS SYSTEM TUMOR; CHEMISTRY; CLASSIFICATION; CYTOLOGY; FETUS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; NERVE CELL; PATHOLOGY; PHENOTYPE; PRENATAL DEVELOPMENT; TUMOR CELL LINE;

ANIMALS; ASTROCYTES; ASTROCYTOMA; BRAIN; CELL LINE, TUMOR; CENTRAL NERVOUS SYSTEM NEOPLASMS; FETUS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MICE; NEOPLASM INVASIVENESS; NEURONS; NUCLEAR PROTEINS; PHENOTYPE; RNA, MESSENGER; TWIST TRANSCRIPTION FACTOR;

EID: 33644873765     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.04352     Document Type: Article

References (70)

1. Weintraub H, Davis R, Tapscott S, Thayer M, Krause M, Benezra R, Blackwell TK, Turner D, Rupp R, Hollenberg S, et al. (1991). The myoD gene family: nodal point during specification of the muscle cell lineage. Science 251 (4995), 761-766.
2. Doyle K, Zhang Y, Baer R, and Bina M (1994). Distinguishable patterns of protein-DNA interactions involving complexes of basic helix-loop-helix proteins. J Biol Chem 269 (16), 12099-12105.
3. Chen ZF and Behringer RR (1995). Twist is required in head mesenchyme for cranial neural tube morphogenesis. Genes Dev 9 (6), 686-699.
4. Soo K, O'Rourke MP, Khoo PL, Steiner KA, Wong N, Behringer RR, and Tam PP (2002). Twist function is required for the morphogenesis of the cephalic neural tube and the differentiation of the cranial neural crest cells in the mouse embryo. Dev Biol 247 (2), 251-270.
5. Zuniga A, Quillet R, Perrin-Schmitt F, and Zeller R (2002). Mouse Twist is required for fibroblast growth factor-mediated epithelial-mesenchymal signalling and cell survival during limb morphogenesis. Mech Dev 114 (1-2), 51-59.
6. Li L, Cserjesi P, and Olson EN (1995). Dermo-1: a novel twist-related bHLH protein expressed in the developing dermis. Dev Biol 172 (1), 280-292.
7. Hebrok M, Fuchtbauer A, and Fuchtbauer EM (1997). Repression of muscle-specific gene activation by the murine Twist protein. Exp Cell Res 232 (2), 295-303.
8. Hamamori Y, Wu HY, Sartorelli V, and Kedes L (1997). The basic domain of myogenic basic helix-loop-helix (bHLH) proteins is the novel target for direct inhibition by another bHLH protein, Twist. Mol Cell Biol 17 (11), 6563-6573.
9. Spicer DB, Rhee J, Cheung WL, and Lassar AB (1996). Inhibition of myogenic bHLH and MEF2 transcription factors by the bHLH protein Twist. Science 272 (5267), 1476-1480.
10. Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, Doglioni C, Beach DH, and Hannon GJ (1999). Twist is a potential oncogene that inhibits apoptosis. Genes Dev 13 (17), 2207-2217.
11. Tamura M and Noda M (1999). Identification of DERMO-1 as a member of helix-loop-helix type transcription factors expressed in osteoblastic cells. J Cell Biochem 72 (2), 167-176.
12. Valsesia-Wittmann S, Magdeleine M, Dupasquier S, Garin E, Jallas AC, Combaret V, Krause A, Leissner P, and Puisieux A (2004). Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell 6 (6), 625-630.
13. Rosivatz E, Becker I, Specht K, Fricke E, Luber B, Busch R, Hofler H, and Becker KF (2002). Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol 161 (5), 1881-1891.
14. Wang X, Ling MT, Guan XY, Tsao SW, Cheung HW, Lee DT, and Wong YC (2004). Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene 23 (2), 474-482.
15. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, and Weinberg RA (2004). Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117 (7), 927-939.
16. Holland EC (2001). Progenitor cells and glioma formation. Curr Opin Neurol 14 (6), 683-688.
17. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, and Cavenee WK (2002). The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61 (3), 215-225; discussion 226-229.
18. Kleihues P and Ohgaki H (1999). Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-Oncology 1 (1), 44-51.
19. Chakravarti A, Zhai G, Suzuki Y, Sarkesh S, Black PM, Muzikansky A, and Loeffler JS (2004). The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 22 (10), 1926-1933.
20. Guha A and Mukherjee J (2004). Advances in the biology of astrocytomas. Curr Opin Neurol 17 (6), 655-662.
21. Palfi S, Swanson KR, De Bouard S, Chretien F, Oliveira R, Gherardi RK, Kros JM, Peschanski M, and Christov C (2004). Correlation of in vitro infiltration with glioma histological type in organotypic brain slices. Br J Cancer 91 (4), 745-752.
22. Yahanda AM, Bruner JM, Donehower LA, and Morrison RS (1995). Astrocytes derived from p53-deficient mice provide a multistep in vitro model for development of malignant gliomas. Mol Cell Biol 15 (8), 4249-4259.
23. Bogler O, Nagane M, Gillis J, Huang HJ, and Cavenee WK (1999). Malignant transformation of p53-deficient astrocytes is modulated by environmental cues in vitro. Cell Growth Differ 10 (2), 73-86.
24. Kinoshita Y, Jarell AD, Flaman JM, Foltz G, Schuster J, Sopher BL, Irvin DK, Kanning K, Kornblum HI, Nelson PS, et al. (2001). Pescadillo, a novel cell cycle regulatory protein abnormally expressed in malignant cells. J Biol Chem 276 (9), 6656-6665.
25. Peyton M, Stellrecht CM, Naya FJ, Huang HP, Samora PJ, and Tsai MJ (1996). BETA3, a novel helix-loop-helix protein, can act as a negative regulator of BETA2 and MyoD-responsive genes. Mol Cell Biol 16 (2), 626-633.
26. Rostomily RC, Bermingham-McDonogh O, Berger MS, Tapscott SJ, Reh TA, and Olson JM (1997). Expression of neurogenic basic helix-loop-helix genes in primitive neuroectodermal tumors. Cancer Res 57 (16), 3526-3531.
27. Kozak M (1987). An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res 15 (20), 8125-8148.
28. Dignam JD, Lebovitz RM, and Roeder RG (1983). Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 11 (5), 1475-1489.
29. Morrison RS and de Vellis J (1981). Growth of purified astrocytes in a chemically defined medium. Proc Natl Acad Sci USA 78 (11), 7205-7209.
30. Lee MS, Lowe GN, Strong DD, Wergedal JE, and Glackin CA (1999). TWIST, a basic helix-loop-helix transcription factor, can regulate the human osteogenic lineage. J Cell Biochem 75 (4), 566-577.
31. Wang SM, Coljee VW, Pignolo RJ, Rotenberg MO, Cristofalo VJ, and Sierra F (1997). Cloning of the human twist gene: its expression is retained in adult mesodermally-derived tissues. Gene 187 (1), 83-92.
32. Brodeur GM (2003). Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3 (3), 203-216.
33. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C, et al. (2002). Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415 (6870), 436-442.
34. Bogler O, Huang HJ, and Cavenee WK (1995). Loss of wild-type p53 bestows a growth advantage on primary cortical astrocytes and facilitates their in vitro transformation. Cancer Res 55 (13), 2746-2751.
35. Dupont J, Fernandez AM, Glackin CA, Helman L, and LeRoith D (2001). Insulin-like growth factor 1 (IGF-1)-induced twist expression is involved in the anti-apoptotic effects of the IGF-1 receptor. J Biol Chem 276 (28), 26699-26707.
36. Leshem Y, Spicer DB, Gal-Levi R, and Halevy O (2000). Hepatocyte growth factor (HGF) inhibits skeletal muscle cell differentiation: a role for the bHLH protein twist and the cdk inhibitor p27. J Cell Physiol 184 (1), 101-109.
37. Davis FG, Freels S, Grutsch J, Barlas S, and Brem S (1998). Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg 88 (1), 1-10.
38. Wrensch M, Minn Y, Chew T, Bondy M, and Berger MS (2002). Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro-Oncology 4 (4), 278-299.
39. Dai C and Holland EC (2003). Astrocyte differentiation states and glioma formation. Cancer J 9 (2), 72-81.
40. Zhu Y and Parada LF (2002). The molecular and genetic basis of neurological tumours. Nat Rev Cancer 2 (8), 616-626.
41. Pathak S (2002). Organ- and tissue-specific stem cells and carcinogenesis. Anticancer Res 22 (3), 1353-1356.
42. O'Rourke MP and Tam PP (2002). Twist functions in mouse development. Int J Dev Biol 46 (4), 401-413.
43. Funato N, Ohtani K, Ohyama K, Kuroda T, and Nakamura M (2001). Common regulation of growth arrest and differentiation of osteoblasts by helix-loop-helix factors. Mol Cell Biol 21 (21), 7416-7428.
44. Howe LR, Watanabe O, Leonard J, and Brown AM (2003). Twist is upregulated in response to Wnt1 and inhibits mouse mammary cell differentiation. Cancer Res 63 (8), 1906-1913.
45. Hamamori Y, Sartorelli V, Ogryzko V, Puri PL, Wu HY, Wang JY, Nakatani Y, and Kedes L (1999). Regulation of histone acetyltransferases p300 and PCAF by the bHLH protein twist and adenoviral oncoprotein E1A. Cell 96 (3), 405-413.
46. Gullaud M, Delanoue R, and Silber J (2003). A Drosophila model to study the functions of TWIST orthologs in apoptosis and proliferation. Cell Death Differ 10 (6), 641-651.
47. Klaunig JE and Kamendulis LM (2004). The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 44, 239-267.
48. Kuruganti PA, Wurster RD, and Lucchesi PA (2002). Mitogen activated protein kinase activation and oxidant signaling in astrocytoma cells. J Neuro-Oncol 56 (2), 109-117.
49. Tada M, Iggo RD, Waridel F, Nozaki M, Matsumoto R, Sawamura Y, Shinohe Y, Ikeda J, and Abe H (1997). Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses. Mol Carcinog 18 (3), 171-176.
50. Nozaki M, Tada M, Kobayashi H, Zhang CL, Sawamura Y, Abe H, Ishii N, and Van Meir EG (1999). Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression. Neuro-Oncology 1 (2), 124-137.
51. Kato H, Kato S, Kumabe T, Sonoda Y, Yoshimoto T, Han SY, Suzuki T, Shibata H, Kanamaru R, and Ishioka C (2000). Functional evaluation of p53 and PTEN gene mutations in gliomas. Clin Cancer Res 6 (10), 3937-3943.
52. Jensen NA, Pedersen KM, Lihme F, Rask L, Nielsen JV, Rasmussen TE, and Mitchelmore C (2003). Astroglial c-Myc overexpression predisposes mice to primary malignant gliomas. J Biol Chem 278 (10), 8300-8308.
53. Hayashi S, Yamamoto M, Ueno Y, Ikeda K, Ohshima K, Soma G, and Fukushima T (2001). Expression of nuclear factor-kappa B, tumor necrosis factor receptor type 1, and c-Myc in human astrocytomas. Neurol Med Chir (Tokyo) 41 (4), 187-195.
54. Thiery JP (2002). Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2 (6), 442-454.
55. Koochekpour S, Jeffers M, Rulong S, Taylor G, Klineberg E, Hudson EA, Resau JH, and Vande Woude GF (1997). Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 57 (23), 5391-5398.
56. Hirano H, Lopes MB, Laws ER Jr, Asakura T, Goto M, Carpenter JE, Karns LR, and VandenBerg SR (1999). Insulin-like growth factor-1 content and pattern of expression correlates with histopathologic grade in diffusely infiltrating astrocytomas. Neuro-Oncology 1 (2), 109-119.
57. Merrill MJ and Edwards NA (1990). Insulin-like growth factor-I receptors in human glial tumors. J Clin Endocrinol Metab 71 (1), 199-209.
58. Bowers DC, Fan S, Walter KA, Abounader R, Williams JA, Rosen EM, and Laterra J (2000). Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways. Cancer Res 60 (15), 4277-4283.
59. Abounader R, Lal B, Luddy C, Koe G, Davidson B, Rosen EM, and Laterra J (2002). In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J 16 (1), 108-110.
60. Wick W, Grimmel C, Wild-Bode C, Platten M, Arpin M, and Weller M (2001). Ezrin-dependent promotion of glioma cell clonogenicity, motility, and invasion mediated by BCL-2 and transforming growth factor-beta2. J Neurosci 21 (10), 3360-3368.
61. Yamamoto S, Wakimoto H, Aoyagi M, Hirakawa K, and Hamada H (1997). Modulation of motility and proliferation of glioma cells by hepatocyte growth factor. Jpn J Cancer Res 88 (6), 564-577.
62. Wick W, Platten M, and Weller M (2001). Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta. J Neuro-Oncol 53 (2), 177-185.
63. Chakravarti A, Loeffler JS, and Dyson NJ (2002). Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62 (1), 200-207.
64. Meng Q, Xu J, Goldberg ID, Rosen EM, Greenwald RA, and Fan S (2000). Influence of chemically modified tetracyclines on proliferation, invasion and migration properties of MDA-MB-468 human breast cancer cells. Clin Exp Metastasis 18 (2), 139-146.
65. Wu CJ, O'Rourke DM, Feng GS, Johnson GR, Wang Q, and Greene MI (2001). The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors. Oncogene 20 (42), 6018-6025.
66. Joy AM, Beaudry CE, Tran NL, Ponce FA, Holz DR, Demuth T, and Berens ME (2003). Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis. J Cell Sci 116 (Pt 21), 4409-4417.
67. Lee MS, Lowe G, Flanagan S, Kuchler K, and Glackin CA (2000). Human Dermo-1 has attributes similar to twist in early bone development. Bone 27 (5), 591-602.
68. Gitelman I (1997). Twist protein in mouse embryogenesis. Dev Biol 189 (2), 205-214.
69. Wolf C, Thisse C, Stoetzel C, Thisse B, Gerlinger P, and Perrin-Schmitt F (1991). The M-twist gene of Mus is expressed in subsets of mesodermal cells and is closely related to the Xenopus X-twi and the Drosophila twist genes. Dev Biol 143 (2), 363-373.
70. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schuler D, Probst-Hensch NM, Maiorka PC, et al. (2004). Genetic pathways to glioblastoma: a population-based study. Cancer Res 64 (19), 6892-6899.